Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.

Tarpley M, Abdissa TT, Johnson GL, Scott JE.

Anticancer Res. 2014 Apr;34(4):1629-35.

2.

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.

Hegedus C, Ozvegy-Laczka C, Apáti A, Magócsi M, Német K, Orfi L, Kéri G, Katona M, Takáts Z, Váradi A, Szakács G, Sarkadi B.

Br J Pharmacol. 2009 Oct;158(4):1153-64. doi: 10.1111/j.1476-5381.2009.00383.x. Epub 2009 Sep 28.

3.
4.

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.

Remsing Rix LL, Rix U, Colinge J, Hantschel O, Bennett KL, Stranzl T, Müller A, Baumgartner C, Valent P, Augustin M, Till JH, Superti-Furga G.

Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27.

PMID:
19039322
5.

Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma.

Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, Sullivan DM, Jove R, Messina JL, Daud AI.

Melanoma Res. 2009 Jun;19(3):167-75. doi: 10.1097/CMR.0b013e328304974c.

PMID:
19434004
6.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

7.

Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

Kim EM, Mueller K, Gartner E, Boerner J.

J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17.

PMID:
23899511
8.

Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.

Levinson NM, Boxer SG.

PLoS One. 2012;7(4):e29828. doi: 10.1371/journal.pone.0029828. Epub 2012 Apr 6.

9.

A phosphoproteomics approach to identify candidate kinase inhibitor pathway targets in lymphoma-like primary cell lines.

Vojvodic M, Hansford LM, Morozova O, Blakely KM, Taylor P, Fathers KE, Moffat J, Marra M, Smith KM, Moran MF, Kaplan DR.

Curr Drug Discov Technol. 2013 Dec;10(4):283-304.

PMID:
23701117
10.

SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.

Vultur A, Buettner R, Kowolik C, Liang W, Smith D, Boschelli F, Jove R.

Mol Cancer Ther. 2008 May;7(5):1185-94. doi: 10.1158/1535-7163.MCT-08-0126.

11.

Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.

Beeharry N, Banina E, Hittle J, Skobeleva N, Khazak V, Deacon S, Andrake M, Egleston BL, Peterson JR, Astsaturov I, Yen TJ.

Cell Cycle. 2014;13(14):2172-91. doi: 10.4161/cc.29214. Epub 2014 Jun 23.

12.

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ.

Breast Cancer Res Treat. 2007 Nov;105(3):319-26. Epub 2007 Feb 1.

PMID:
17268817
13.

Src as a Therapeutic Target in Biliary Tract Cancer.

Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.

Mol Cancer Ther. 2016 Jul;15(7):1515-24. doi: 10.1158/1535-7163.MCT-16-0013. Epub 2016 Apr 22.

14.

Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.

Karim SA, Creedon H, Patel H, Carragher NO, Morton JP, Muller WJ, Evans TR, Gusterson B, Sansom OJ, Brunton VG.

J Pathol. 2013 Aug;230(4):430-40. doi: 10.1002/path.4202.

PMID:
23616343
15.

Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer.

Gordian E, Li J, Pevzner Y, Mediavilla-Varela M, Luddy K, Ohaegbulam K, Daniel KG, Haura EB, Muñoz-Antonia T.

PLoS One. 2014 Dec 11;9(12):e114131. doi: 10.1371/journal.pone.0114131. eCollection 2014.

16.

Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.

Nguyen T, Hawkins E, Kolluri A, Kmieciak M, Park H, Lin H, Grant S.

Leuk Res. 2015 Jan;39(1):65-71. doi: 10.1016/j.leukres.2014.10.009. Epub 2014 Nov 11.

17.

Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.

Eustace AJ, Crown J, Clynes M, O'Donovan N.

J Transl Med. 2008 Sep 29;6:53. doi: 10.1186/1479-5876-6-53.

18.

Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.

Hsyu PH, Pignataro DS, Matschke K.

Eur J Clin Pharmacol. 2017 Jan;73(1):57-63. doi: 10.1007/s00228-016-2115-0. Epub 2016 Oct 7.

PMID:
27717999
19.

Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.

Zheng MW, Zhang CH, Chen K, Huang M, Li YP, Lin WT, Zhang RJ, Zhong L, Xiang R, Li LL, Liu XY, Wei YQ, Yang SY.

Mol Cancer Ther. 2016 Mar;15(3):366-78. doi: 10.1158/1535-7163.MCT-15-0501. Epub 2015 Dec 31.

20.

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.

Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, Corey SJ.

Br J Cancer. 2009 Jul 7;101(1):38-47. doi: 10.1038/sj.bjc.6605101. Epub 2009 Jun 9.

Supplemental Content

Support Center